A Study Evaluating the Safety, Tolerability, and Pharmacokinetics of GDC-0425 Administered With and Without Gemcitabine in Patients With Refractory Solid Tumors or Lymphoma
This is an open-label, multicenter, Phase I, dose-escalation study to assess the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of GDC-0425 administered with and without gemcitabine.
Solid Tumor
DRUG: GDC-0425|DRUG: gemcitabine
Incidence of all adverse events graded according to NCI CTCAE, v4.0, Up to 1 year|Incidence of dose limiting toxicities (DLTs), Up to 35 days|Pharmacokinetic property of GDC-0425: determination of plasma drug concentration, Up to 12 months or early study discontinuation|Pharmacokinetic property of GDC-0425: exposure, Up to 12 months or early study discontinuation|Pharmacokinetic property of GDC-0425: half-life, Up to 12 months or early study discontinuation|Severity of all adverse events graded according to NCI CTCAE, v4.0, Up to 1 year
Antitumor activity of GDC-0425 in combination with gemcitabine: determination of tumor response using RECIST v1.1 for patients with measurable disease, Up to 12 months or early study discontinuation
This is an open-label, multicenter, Phase I, dose-escalation study to assess the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of GDC-0425 administered with and without gemcitabine.